The Latest Breaking News from Revvity

Revvity shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

Revvity has lagged behind the broader market this year, and Wall Street analysts maintain a cautiously optimistic outlook on its future potential.

A Relative Strength Rating upgrade for Revvity shows improving technical performance. Will it continue?

Revvity is set to release its third-quarter earnings next month, with analysts projecting a slight decline in profit.

Despite Revvity’s underperformance compared to its industry peers over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Revvity has significantly underperformed the broader market this year, but Wall Street analysts are moderately optimistic about the stock’s prospects.

Revvity will release its second-quarter earnings later this month, and analysts anticipate a single-digit profit dip.

What you need to know… The S&P 500 Index ($SPX ) (SPY ) on Thursday closed down -0.34%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.03%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.53%. Stocks on Thursday settled mixed, with the S&P...

The Boldon company became part of American life sciences group Revvity two years ago